Histoplasmosis Treatment Market Report 2026

The histoplasmosis treatment market size has grown strongly in recent years. It will grow from $5.5 billion in 2025 to $5.94 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing incidence of fungal infections, wider use of antifungal medications, expansion of hospital treatment facilities, improved diagnostic awareness, availability of broad-spectrum antifungal drugs.

The histoplasmosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for advanced antifungal formulations, rising focus on immunocompromised patient care, expansion of oral antifungal therapies, growing investments in infectious disease research, increasing adoption of guideline-based treatment protocols. Major trends in the forecast period include increasing use of targeted antifungal therapies, rising adoption of early diagnostic treatment protocols, growing focus on severe fungal infection management, expansion of hospital-based antifungal care, enhanced emphasis on patient-specific treatment approaches.

The rising incidence of chronic diseases is expected to drive the growth of the histoplasmosis treatment market in the coming years. Chronic diseases are long-term illnesses lasting three months or more and can worsen over time. Histoplasmosis treatment helps improve respiratory health, reduce inflammation, enhance immune system function, and improve the quality of life for patients with chronic conditions. For example, in April 2025, the Centers for Disease Control and Prevention (CDC) reported that in 2023, approximately 194 million U.S. adults, or 76.4%, had at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Consequently, the increasing incidence of chronic diseases is fueling the expansion of the histoplasmosis treatment market.

The growing prevalence of human immunodeficiency virus (HIV) is also expected to support the growth of the histoplasmosis treatment market. HIV is a virus that attacks the immune system, specifically targeting CD4 (T) cells, which weakens the body’s ability to fight infections and diseases. Histoplasmosis treatment is essential for AIDS patients to manage fungal infections, prevent disseminated disease, and reduce mortality through antifungal medications such as itraconazole or amphotericin B. For instance, in August 2024, the Minority HIV/AIDS Fund (MHAF) reported that in 2023, approximately 39.9 million people worldwide were living with HIV, including 38.6 million adults and 1.4 million children. Therefore, the rising prevalence of HIV is contributing to the growth of the histoplasmosis treatment market.

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired the CIMERLI business from Coherus for an undisclosed amount. This acquisition aims to strengthen Sandoz’s ophthalmic portfolio by incorporating CIMERLI, positioning the company as a leader in the U.S. biosimilar market and expanding access to affordable treatments for vision impairment. Coherus BioSciences Inc., based in the United States, specializes in providing treatments for histoplasmosis.

Major companies operating in the histoplasmosis treatment market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol Myers Squibb, AstraZeneca Plc, Abbott laboratories, GSK Plc, Eli Lilly and Company, Gilead Sciences, Teva Pharmaceutical Industries Ltd., Astellas pharma US Inc., Mylan N.V., Biogen Inc., Bausch Health Companies Inc., Mitsubishi Tanabe Pharma Corporation, AB Science, Ionis Pharmaceuticals Inc., Advanz Pharma Corp., Leadiant Biosciences, IMMY, Sigma Tau Pharmaceuticals Inc.

North America was the largest region in the histoplasmosis treatment market in 2025. The regions covered in the histoplasmosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the histoplasmosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the histoplasmosis treatment market by increasing costs of imported antifungal drug ingredients, formulation excipients, packaging materials, and pharmaceutical manufacturing equipment. Hospital pharmacies and drug suppliers in North America and Europe are most affected due to reliance on imported APIs, while Asia-Pacific faces cost pressure on generic drug production. These tariffs are increasing treatment costs and affecting drug availability timelines. However, they are also promoting domestic pharmaceutical manufacturing, regional API sourcing, and improved supply chain resilience for essential antifungal medications.

The histoplasmosis treatment market research report is one of a series of new reports that provides histoplasmosis treatment market statistics, including histoplasmosis treatment industry global market size, regional shares, competitors with a histoplasmosis treatment market share, detailed histoplasmosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the histoplasmosis treatment industry. This histoplasmosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Histoplasmosis treatment encompasses medical interventions and therapies used to manage and eradicate infections caused by the Histoplasma capsulatum fungus. This fungus is commonly found in soil, particularly in areas with large accumulations of bird or bat droppings. The treatment approach depends on the severity of the infection, the patient’s overall health, and the presence of any underlying medical conditions.

The primary drug types used in histoplasmosis treatment include amphotericin B, itraconazole, ketoconazole, and others. Amphotericin B is a potent antifungal medication employed to treat severe and potentially life-threatening fungal infections. Treatments can be administered through various routes, including injectable, oral, and other methods, and are used for different patient groups, including pediatric and adult populations. These therapies are provided by a range of end users, such as hospital pharmacies, private clinics, drug stores, retail pharmacies, e-commerce platforms, and others.

The histoplasmosis treatment consists of sales of antifungal medications and posaconazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.